Literature DB >> 23597946

Possible use of Trichuris suis ova in autism spectrum disorders therapy.

Dario Siniscalco1, Nicola Antonucci.   

Abstract

Autism and autism spectrum disorders (ASDs) are heterogeneous, severe neurodevelopmental pathologies. The main core symptoms are: dysfunctions in social interactions and communication skills, restricted interests, repetitive and stereotypic verbal and non-verbal behaviors. Several biochemical processes are associated with ASDs: oxidative stress; endoplasmic reticulum stress; decreased methylation capacity; limited production of glutathione; mitochondrial dysfunction; intestinal dysbiosis; increased toxic metal burden; immune dysregulation. Current available treatments for ASDs can be divided into behavioral, nutritional and medical approaches, although no defined standard approach exists. Current drugs fail to benefit the ASD core symptoms and can have marked adverse effects, are mainly palliative and only sometimes efficacy in attenuating specific autistic behaviors. Helminthic therapy shows potential for application as anti-inflammatory agent. Several human diseases can be treated by helminths (i.e. inflammatory bowel disease, asthma, multiple sclerosis and autoimmune diabetes). Trichuris suis ova (TSO) show strong immunomodulatory properties. Authors hypothesize that TSO could be useful in addressing ASD immune dysregulations. TSO could be a novel therapeutic option for ASD management.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23597946     DOI: 10.1016/j.mehy.2013.03.024

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  9 in total

Review 1.  Nematodes and human therapeutic trials for inflammatory disease.

Authors:  D E Elliott; J V Weinstock
Journal:  Parasite Immunol       Date:  2017-04-18       Impact factor: 2.280

Review 2.  Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders.

Authors:  Amir Abdoli; Hoda Mirzaian Ardakani
Journal:  Metab Brain Dis       Date:  2019-07-27       Impact factor: 3.584

Review 3.  Mesenchymal stem cells in treating autism: Novel insights.

Authors:  Dario Siniscalco; James Jeffrey Bradstreet; Nataliia Sych; Nicola Antonucci
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

4.  Approaches to studying and manipulating the enteric microbiome to improve autism symptoms.

Authors:  Richard E Frye; John Slattery; Derrick F MacFabe; Emma Allen-Vercoe; William Parker; John Rodakis; James B Adams; Rosa Krajmalnik-Brown; Ellen Bolte; Stephen Kahler; Jana Jennings; Jill James; Carl E Cerniglia; Tore Midtvedt
Journal:  Microb Ecol Health Dis       Date:  2015-05-07

Review 5.  Parasites-allergy paradox: Disease mediators or therapeutic modulators.

Authors:  Mohammed A Afifi; Asif A Jiman-Fatani; Sherif El Saadany; Mahmoud A Fouad
Journal:  J Microsc Ultrastruct       Date:  2015-03-17

Review 6.  Stem Cell-Derived Exosomes in Autism Spectrum Disorder.

Authors:  Nicola Alessio; Anna Lisa Brigida; Gianfranco Peluso; Nicola Antonucci; Umberto Galderisi; Dario Siniscalco
Journal:  Int J Environ Res Public Health       Date:  2020-02-04       Impact factor: 3.390

Review 7.  Epigenetic findings in autism: new perspectives for therapy.

Authors:  Dario Siniscalco; Alessandra Cirillo; James Jeffrey Bradstreet; Nicola Antonucci
Journal:  Int J Environ Res Public Health       Date:  2013-09-11       Impact factor: 3.390

Review 8.  Perspectives on the use of stem cells for autism treatment.

Authors:  Dario Siniscalco; James Jeffrey Bradstreet; Nataliia Sych; Nicola Antonucci
Journal:  Stem Cells Int       Date:  2013-10-10       Impact factor: 5.443

9.  The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages.

Authors:  Dario Siniscalco; James Jeffrey Bradstreet; Alessandra Cirillo; Nicola Antonucci
Journal:  J Neuroinflammation       Date:  2014-04-17       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.